Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave s ex-CEO Receives Severance; New VP at Orchid Cellmark; Others

John Puisis, president and CEO of Third Wave Technologies resigned from the company late last week.


According to documents filed with the Securities Exchange Commission, Puisis received a severance package that includes $880,000, of which $220,000 has been paid, and the remainder will be paid in 18 monthly installments. Puisis will also receive $33,572 in cash, to be paid in 12 monthly installments, and immediate vesting of any unvested stock options that he'd received. Puisis will collect a maximum of $15,000 in outplacement consulting services.


GE Healthcare veteran Kevin Conroy, currently Third Wave's vice president and general counsel, replaced Puisis.

GE Healthcare named Gene Cartwright as president of its Molecular Diagnostics business to lead the development of the in-vitro clinical diagnostics business.


He will be based in Piscataway, NJ. 


Cartwright was previously at Abbott Laboratories as vice-president of strategic programs for its molecular diagnostics business. He received his PhD in chemistry from Stanford University.

Orchid Cellmark named Gordon J. Brown to fill the newly created position of senior vice-president of global laboratory operations, the company said today.  The appointment is effective Jan. 1, 2006.


Brown most recently served as a vice-president and general manager of Esoterix, a subsidiary of Laboratory Corporation of America. Before moving to Esoterix in 2004, he was program director of front-end operations, director of integration and director of logistics at Quest Diagnostics. From 1987 to 1995, he held various production planning and manufacturing positions at American Home Products, now Wyeth.


Brown has a BS in business logistics from Pennsylvania State University and a MBA. in finance from Fordham University. 

Jeffrey Skolnick is leaving his position as director of the Buffalo Center of Excellence in Bioinformatics at SUNY-Buffalo to join the Georgia Institute of Technology as the Georgia Research Alliance Eminent Scholar in Computational Systems Biology.


According to a Georgia Tech press release, Skolnick will bring 19 research scientists and technicians "and more than $1.5 million in federal funding" to the university. Skolnick and his team will be housed in the School of Biology, a unit in the College of Sciences.

Kenneth Buetow has been appointed to the new position of Associate Director for Bioinformatics and Information Technologies at the National Cancer Institute, according to a recent NCI Cancer Bulletin.


Buetow was previously director of the NCI Center for Bioinformatics. In his new position, Buetow will "manage and execute information technology and bioinformatics initiatives that will lead to the usage of common tools, standards, and datasets across NCI; assist internal teams in adopting and leveraging NCI's cancer Biomedical Informatics Grid (caBIG) infrastructure; review and update NCI's existing and planned bioinformatics programs and activities; make recommendations for the creation of a standing group that will provide technical guidance on new projects; and regularly report to the NCI Executive Committee, of which he is a member," the Cancer Bulletin said.


Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.